Preview a range of resources designed to support you and your GILENYA®▼ (fingolimod) patients during face-to-face or virtual conversations.
This website is intended for healthcare professionals only. Please do not share links to this page with patients. You can download the resources to share with patients separately.
WHAT TO EXPECT WHEN STARTING GILENYA
A video to show your patients what it’s like to start receiving treatment with GILENYA.
GILENYA PATIENT BOOKLET
A booklet for your patients who have been prescribed GILENYA, which provides important information about taking GILENYA and practical advice about wellbeing while on treatment.
THE YOUNG PERSON’S GUIDE TO GILENYA
A booklet to help your paediatric patients understand more about their treatment.
SYMTRAC™
A free app to help your patients keep track of their MS.
RECOGNISING YOUR MS SYMPTOMS
A guide to help your patients recognise MS symptoms and what to do in case they think they are having a relapse.
PAEDIATRIC LICENCE: PARADIGMS STUDY
An animated overview of the PARADIGMS study, a landmark phase III trial of GILENYA in paediatric patients with RRMS.
GILENYA DISCUSSION GUIDE
A guide for you to use in conversations with your patients who have been prescribed GILENYA, but which must not be given or sent to patients. The guide helps you introduce GILENYA and explain information that patients need to know before commencing treatment.
PATIENT, PARENT AND CAREGIVER GUIDE
A booklet for GILENYA patients or their parents or caregivers which explains what GILENYA is and contains other important information about the treatment.
PREGNANCY-SPECIFIC PATIENT REMINDER CARD
A card to give to patients to explain the warnings and contraindications related to pregnancy associated with GILENYA.
PRESCRIBER’S CHECKLIST
A checklist for prescribers listing important points to remember before, during and after a patient has been prescribed GILENYA.
SUMMARY OF PRODUCT CHARACTERISTICS FOR GILENYA
The summary of product characteristics for GILENYA.
Clicking the View button will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.1
Gd+, gadolinium-enhancing; HCP, healthcare professional; MRI, magnetic resonance imaging; MS, multiple sclerosis; RES, rapidly evolving severe; RRMS, relapsing-remitting multiple sclerosis.
Reference
- GILENYA (fingolimod) Summary of Product Characteristics.
